Ramón CI, Soriano GJL, Morales MD, Lima PM, Batista AN, Fleites CV, González MM, Gutiérrez RAR

Language: Spanish
References: 31
Page: 1-13
PDF size: 418.91 Kb.

ABSTRACT

Introduction: Zoledronic Acid improves the quality of life of patients suffering from prostate cancer.
Objectives: To assess the health-related quality of life using EORTC QLQ–BM22 questioner in patients suffering from prostate cancer, treated with zoledronic acid.v Method: A prospective-descriptive study was carried out in 71 patients suffering from prostate cancer involving bones, with ages ranging between 18 and 80 years, and who were treated in the oncology service at Hermanos Ameijeiras Hospital. The ECOG was less than 3, life expectancy> 6 months, and follow-up of at least twelve months. Zoledronic acid was administered every 21-28 days. The visual analog scale and EORTC QLQ-BM22 module were applied.v Results: The patients had median age of 71 years, Gleason ≥ 8: in 57.7% of the patients, PSA at diagnosis ≥ 20 ng/mL: 70.4%, ECOG 1: 67.6%, and stage IV as initial presentation: 50.7%. Bone metastases without visceral intake: 84.5%, in vertebrae 36.6%, <3 sites 66.2%, and blast bone metastases 60.6%. Skeletal events related to zoledronic acid before 7.9% (fracture), and after 5.6% (anti-allergic radiotherapy). At twelve months, according to the visual analog scale, a complete response was achieved, 71%, and a partial response, 29% (p <0.05). After the application of EORTC QLQ-BM22 module, a significant decrease was found in both the symptom and functional scales, regardless of other factors.
Conclusions: Specific treatments for prostate cancer combined with zoledronic significantly improve pain and health-related quality of life in patients with bone metastases.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: Cancer J Clin. 2019;69:7-34.http://dx.doi.org/10.21037/atm.2020.03.55

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA:Cancer J Clin. 2018;68:394-24. http://dx.doi.org/10.21037/atm.2020.03.55

3. Anuario Estadístico de Cuba 2018. Edición 2019. MINSAP, Dirección Nacional de RegistrosMédicos y Estadísticas de Salud. La Habana, 2019[acceso: 30/04/2020]. Disponible en:http://temas.sld.cu

4. Esposito M, Guise T, Kang Y. The biology of bone metastasis. Cold Spring Harb Perspect Med.2018;8(6): a031252. http://dx.doi.org/10.1101/cshperspect.a031252

5. Atkinson EG, Delgado‐Calle J. The Emerging Role of Osteocytes in Cancer in Bone. JBMR Plus.2019;3(3):e10186. http://dx.doi.org/10.1002/jbm4.10186

6. Xiangyu Z. Interactions between cancer cells and bone microenvironment promote bonemetastasis in prostate cancer. Cancer Commun (Lond). 2019;39:76.http://dx.doi.org/10.1186/s40880-019-0425-1

7. Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic valueof biochemical recurrence following treatment with curative intent for prostate cancer: asystematic review. Eur Urol. 2019;75:967-87. https://doi.org/10.1016/j.eururo.2018.10.011

8. Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact ofpositron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence ofprostate cancer: results from the LOCATE Trial. J Urol. 2019;201:322-31.http://dx.doi.org/10.1016/j.juro.2018.08.050

9. Santini D, Berruti A, Di Maio M, Procopio G, Bracarda S, Ibrahim T, et. al. Bone healthmanagement in the continuum of prostate cancer disease: a review of the evidence with an expertpanel opinion. ESMO Open. 2020;5(2):e000652. http://dx.doi.org/10.1136/esmoopen-2019-000652

10. El Badri SAM, Salawu A, Brown JE. Bone health in men with prostate cancer. Curr OsteoporosRep. 2019;17(6):527-37. http://dx.doi.org/10.1007/s11914-019-00536-8

11. Taxel P, Faircloth E, Idrees E, Van Poznak C. Cancer treatment–induced bone loss in womenwith breast cancer and men with prostate cancer. J Endocr Soc. 2018;2(7):574-88.http://dx.doi.org/10.1210/js.2018-00052

12. Tesfamariam YM, Macherey S, Kuhr K, Becker I, Monsef I, Jakob T, et al. Bisphosphonates orRANK ligand-inhibitors for men with prostate cancer and bone metastases: a Cochrane Review andnetwork meta-analysis. Cochrane Database of Systematic Reviews. 2018.http://dx.doi.org/10.1002/14651858.CD013020

13. Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Bisphosphonates, much more than onlydrugs for bone diseases. Eur J Pharmacol. 2020;866:172773. https://dx.doi.org/10.1016/j.ejphar.2019.172773

14. Body JJ, von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F, et al. A real-world studyassessing the use of bone-targeted agents and their impact on bone metastases in patients withprostate cancer treated in clinical practice in Europe. J Bone Oncol. 2019;14:100212.http://dx.doi.org/10.1016/j.jbo.2018.100212

15. Walz S, Maas M, Stenzl A, Todenhöfer T. Bone Health Issues in Patients with Prostate Cancer:An Evidence-Based Review. World J Mens Health. 2020;38(2):151-63.http://dx.doi.org/10.5534/wjmh.190044

16. Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarró M, Kaye JA. Incidence ofskeletal-related events in patients with castration-resistant prostate cancer: an observationalretrospective cohort study in the US. Prostate Cancer. 2019;5971615.http://dx.doi.org/10.1155/2019/5971615

17. García A, González J, Matos E, Cuendías B, Caballero I, Ruíz E, et al. Cáncer de Próstata. En:Unidad Funcional de Tumores. Tomo 1. La Habana. Editorial de Ciencias Médicas. 2012. p. 142-64.

18. Saad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, et al. Diseasecharacteristics and completion of treatment in patients with metastatic castration-resistantprostate cancer treated with radium-223 in an International Early Access Program. Clin GenitourinCancer. 2019;17(5):348-55.e5. http://dx.doi.org/10.1016/j.clgc.2019.05.012

19. Smith M, Parker Ch, Saad F, Miller K, Tombal B, Sing Ng Q, et al. Addition of radium-223 toabiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostatecancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3trial. Lancet Oncol. 2019;20(3):408-19. http://dx.doi.org/10.1016/S1470-2045(18)30860-X

20. El Hachem G, Oliveira Rocha F, Pepersack Th, Jounblat Y, Drowart A, Dal Lago L, et al.Advances in pain management for older patients with cancer. Ecancermedicalscience.2019;13:980. http://dx.doi.org/10.3332/ecancer.2019.980

21. Cheng Y, Lin Zhuo L, Pan Y, Wang Sh, Zong J, Sun W, et al. Treatment patterns of prostatecancer with bone metastasis in Beijing: A real‐world study using data from an administrativeclaims database. Pharmacoepidemiol Drug Saf. 2019;28(11):1501-09.http://dx.doi.org/10.1002/pds.4874

22. Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, et al. Bisphosphonates foradvanced prostate cancer. Cochrane Database of Systematic Reviews 2017.http://dx.doi.org/10.1002/14651858.CD006250.pub2

23. Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, et al. Prevention of bonemetastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid:efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2015;67(3):482-91.https://doi.org/10.1016/j.eururo.2014.02.014

24. Vale CL, Burdett S, Rydzewska LH. Addition of docetaxel or bisphosphonates to standard ofcare in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic reviewand meta-analyses of aggregate data. Lancet Oncol. 2016;17:243-56.http://dx.doi.org/10.1016/S1470-2045(15)00489-1

25. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, et al. A phase III multicenter,randomized, controlled study of combined androgen blockade with versus without zoledronic acidin prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J ClinOncol. 2017;22(1):166-73. http://dx.doi.org/10.1007/s10147-016-1037-2

26. Kurosaka S, Satoh T. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients withpainful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. AnnNucl Med. 2012;26(6):485-91. http://dx.doi.org/ 10.1007/s12149-012-0598-z

27. Chen Zh, Wang Ch, Ma X, Sun W, Shen J, Sun M, et al. Evaluation of quality of life using EORTCQLQ-BM22 in patients with bone metastases after treatment with magnetic resonance guidedfocused ultrasound. Orthop Surg. 2018;10(3):264-71. http://dx.doi.org/10.1111/os.12383

28. De Vincentis G, Frantellizzi V, Follacchio GA, Alessio Farcomeni A, Pani A, Samaritani R, et al.No evidence of association between psychological distress and pain relief in patients with bonemetastases from castration resistant prostate cancer treated with Radium. Eur J Cancer Care(Engl). 2019;28(5):13112. http://dx.doi.org/10.1111/ecc.13112

29. Wang J, Serafini AN. Palliation of metastatic bone pain with radiolabeled phosphonates. En:Ahmadzadehfar H, Biersack HJ, Freeman L, Zuckier L. (eds) Clinical Nuclear Medicine. Springer,Cham. 2020. https://doi.org/10.1007/978-3-030-39457-8_30

30. Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, et al. On behalf of the EuropeanOrganization for Research Treatment of Cancer Quality of Life Group. International field-testing ofthe reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of lifein patients with bone metastases. Cancer. 2012;118:1457-65. https://doi.org/10.1002/cncr.26410

31. Ramón I, Soriano JL, Batista N, Lima M, Morales D, Fleites V. Calidad de vida en pacientes conmetástasis óseas por cáncer de mama tratadas con ácido zoledrónico. Acta Médica. 2018[acceso:20/06/2020];18(2). Disponible en: http://bvs.sld.cu/revistas/act/vol19_2_18/actsu218.htm